September 25, 2017 |
First Ever Clinical Trial of Allogeneic Bone Cell Therapy Product
June 25, 2014  | 

Gosselies, BE – Bone Therapeutics, a regenerative therapy company addressing unmet medical needs in the field of bone diseases and orthopedics, today announces that the first patient has been treated with its novel allogeneic osteoblastic (bone-forming) cell therapy product ALLOB® in its phase I/IIa study for the treatment of delayed union fractures.

ALLOB is the first ever allogeneic differentiated[1] osteoblastic cell therapy product developed for the treatment of orthopedic conditions. Allogeneic cell therapy involves the harvesting of cells from a healthy, universal donor, rather than from the patient being treated. ALLOB has shown safety and efficacy in preclinical studies and does not require any immunosuppressive side therapy. 

ALLOB has the potential to become a first-line treatment for impaired fracture healing, thanks to its minimally invasive percutaneous administration. Delayed union fractures, defined by the absence of fracture healing after 3 months, affect around 600,000 to 900,000 new patients a year in Europe and the US.  The current standard of care for delayed union fractures involves highly invasive surgery, which takes up to several hours followed by a long hospitalization. By contrast, this first administration of ALLOB required about 20 minutes and took place at the day-clinic. ALLOB is injected by the orthopedic surgeon in a single dose percutaneously, directly into the fracture site. No side-effects have yet been reported. Continue>

Page | 1 2
Suggested Articles